ChartMill assigns a Buy % Consensus number of 84% to GOSS. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-09-11 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2025-09-10 | UBS | Upgrade | Neutral -> Buy |
| 2025-08-06 | Wedbush | Maintains | Outperform -> Outperform |
| 2025-07-14 | ScotiaBank | Initiate | Sector Outperform |
| 2025-05-16 | Wedbush | Reiterate | Outperform -> Outperform |
| 2025-05-16 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-04-17 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-03-18 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-14 | Wedbush | Reiterate | Outperform -> Outperform |
| 2025-01-30 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-09-17 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-30 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-13 | Wedbush | Reiterate | Outperform -> Outperform |
| 2024-06-25 | Oppenheimer | Initiate | Outperform |
| 2024-06-17 | Goldman Sachs | Maintains | Buy -> Buy |
| 2024-05-20 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-08 | Wedbush | Reiterate | Outperform -> Outperform |
| 2024-05-06 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-03-27 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2024-03-06 | Wedbush | Reiterate | Outperform -> Outperform |
| 2024-03-06 | Goldman Sachs | Maintains | Buy -> Buy |
| 2024-03-06 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-01-08 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-12-19 | Wedbush | Reiterate | Outperform -> Outperform |
| 2023-11-10 | Wedbush | Maintains | Outperform -> Outperform |
| 2023-08-11 | Wedbush | Reiterate | Outperform -> Outperform |
| 2023-08-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-07-26 | Wedbush | Maintains | Outperform -> Outperform |
| 2023-07-26 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
15 analysts have analysed GOSS and the average price target is 9.62 USD. This implies a price increase of 188.8% is expected in the next year compared to the current price of 3.33.
The consensus rating for GOSSAMER BIO INC (GOSS) is 84 / 100 . This indicates that analysts generally have a positive outlook on the stock.